A post hoc analysis of linaclotide in pediatric patients with functional constipation and neurodevelopmental disorders

CONCLUSIONS: In children with FC and comorbid NDD, linaclotide 72 µg once daily was associated with improved constipation outcomes, high adherence, and a well-tolerated safety profile, similar to that seen in the overall study population.

via https://pubmed.ncbi.nlm.nih.gov/41913506/?utm_source=Other&utm_medium=rss&utm_campaign=None&utm_content=1lqZ3NPYysePVKsoyz66mDSgu4veDGJwnUBS47TBQPoOuNZY5J&fc=None&ff=20260409011005&v=2.19.0.post6+133c1fe